Ireland-based Covidien has received CE Mark approval for its Nellcor bedside SpO2 patient monitoring system, PM100N.
Covidien claims the system is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes that complies with standards for medical electrical equipment used in the home health care environment.
The system offers continuous monitoring of blood oxygenation (SpO2) and pulse rate, to help clinicians detect and respond to dangerous respiratory events, along with patient trend data to allow clinicians to evaluate their course of action.
During low patient perfusion, motion and other forms of signal interference, the new system offers speed and accuracy, as well as reliable pulse oximetry readings.
The PM100N features SatSeconds Alarm Management technology that helps distinguish between serious and minor events.
The technology is available only on Covidien patient monitors and helps in differentiating serious and minor events, while reducing clinically insignificant desaturation alarms.
Covidien said the monitor can also be password-protected to prevent lay users from inadvertently modifying settings.
Covidien respiratory and monitoring solutions chief medical officer Dr Scott Kelley said: "The availability of solutions to enable safe, quality care for patients in all settings, including the home, is something we are focused on at Covidien.
"This new system includes all of the leading Nellcor technology that clinicians have trusted for more than 30 years, with additional features that make it well suited to the home health care environment."
The Nellcor Bedside SpO2 Patient Monitoring System is available for sale in the European Economic Area (EEA), Australia and New Zealand.